Aqueous-based pharmaceutical composition
Patent 5976573 Issued on November 2, 1999. Estimated Expiration Date: 
July 3, 2016. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
July 3, 2016. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent References 2156254 3035984 3780176 3809294 3897779 Method and preparation for administration to the mucosa of the oral or nasal cavity Method and preparation for administration to the mucosa of the oral or nasal cavity Powdery pharmaceutical composition and powdery preparation for application to the nasal mucosa, and method for administration thereof Ocular insert housing steroid in two different therapeutic forms Androstane carbothioates InventorAssigneeApplicationNo. 678465 filed on 07/03/1996US Classes:424/489, Particulate form (e.g., powders, granules, beads, microcapsules, and pellets)424/45, Organic pressurized fluid424/46, Powder or dust containing424/400, PREPARATIONS CHARACTERIZED BY SPECIAL PHYSICAL FORM424/490, Coated (e.g., microcapsules)424/492, Gelatin424/497, Containing solid synthetic polymers514/174, -O-C-O- is part of a hetero ring (e.g., acetonide, etc.)514/951, POWDERS, GRANULES OR PARTICLES OF SPECIFIED MESH OR PARTICLE SIZE514/975CHARACTERIZED BY THE DESIGNATED SURFACTANT USEDExaminersPrimary: Mosher, Mary E.Assistant: Salimi, Ali R. Attorney, Agent or FirmInternational ClassesA61K 009/14A61K 009/00 A61K 039/58 AbstractAn aqueous pharmaceutical composition which is capable of being sprayed into the nasal cavity of an individual and which comprises: (A) a pharmaceutically effective amount of solid particles of medicament which is effective in treating a bodily condition by virtue of its being present on the mucosal surfaces of the nasal cavity; and (B) a suspending agent in an amount effective to maintain said particles dispersed uniformly in the composition and to impart to the composition the following thixotropic properties: (i) the viscosity of the position in unsheared form is relatively high, with the composition being in gel-like form; (ii) as the composition is subjected to shear (shaken) in preparation for spraying, the viscosity of the composition becomes relatively low and such that the composition in the form of a mist flows readily into the nasal passages for deposit on the mucosal surfaces of the nasal cavity; and (iii) in deposited form on the mucosal surfaces, the viscosity of the composition is relatively high and such that it resists being cleared from the mucosal surfaces by the inherent mucocillary forces which are present in the nasal cavity, a method of use of the composition and a method for preparation of the composition, including in preferred form the use of anti-inflammatory steroid, for example, triamcinolone acetonide, and an odorless form of the composition.Other References
Field of SearchOrganic pressurized fluidPowder or dust containing Particulate form (e.g., powders, granules, beads, microcapsules, and pellets) Coated (e.g., microcapsules) Gelatin Containing solid synthetic polymers PREPARATIONS CHARACTERIZED BY SPECIAL PHYSICAL FORM POWDERS, GRANULES OR PARTICLES OF SPECIFIED MESH OR PARTICLE SIZE CHARACTERIZED BY THE DESIGNATED SURFACTANT USED -O-C-O- is part of a hetero ring (e.g., acetonide, etc.) | |
